JP5261575B2 - 化学化合物 - Google Patents
化学化合物 Download PDFInfo
- Publication number
- JP5261575B2 JP5261575B2 JP2011515631A JP2011515631A JP5261575B2 JP 5261575 B2 JP5261575 B2 JP 5261575B2 JP 2011515631 A JP2011515631 A JP 2011515631A JP 2011515631 A JP2011515631 A JP 2011515631A JP 5261575 B2 JP5261575 B2 JP 5261575B2
- Authority
- JP
- Japan
- Prior art keywords
- thiazolidine
- dione
- phenyl
- methylidene
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c(c(*)c1*)cc(C=O)c1F Chemical compound *c(c(*)c1*)cc(C=O)c1F 0.000 description 1
- PCPARURGLGSLFB-CJAAZZPWSA-N CN(C)[C@@H](CC1)CN1c(c(/C=C(/C(N1)=O)\SC1=O)ccc1)c1[Br]=C Chemical compound CN(C)[C@@H](CC1)CN1c(c(/C=C(/C(N1)=O)\SC1=O)ccc1)c1[Br]=C PCPARURGLGSLFB-CJAAZZPWSA-N 0.000 description 1
- SYFAMQSVMVHCIS-NSHDSACASA-N CN(C)[C@@H](CC1)CN1c1c(C=O)cccc1Br Chemical compound CN(C)[C@@H](CC1)CN1c1c(C=O)cccc1Br SYFAMQSVMVHCIS-NSHDSACASA-N 0.000 description 1
- DCEQRIXNZLRPRR-PXNMLYILSA-N COc(c(OC)c1)cc(/C=C(/C(N2)=O)\SC2=O)c1N(CC1)CC1NCCO Chemical compound COc(c(OC)c1)cc(/C=C(/C(N2)=O)\SC2=O)c1N(CC1)CC1NCCO DCEQRIXNZLRPRR-PXNMLYILSA-N 0.000 description 1
- VWJNQFFHSJTVGQ-CJAAZZPWSA-N C[n]1c(C(N[C@@H](CC2)CN2c(c(/C=C(/C(N2)=O)\SC2=O)ccc2)c2Cl)=O)ncc1 Chemical compound C[n]1c(C(N[C@@H](CC2)CN2c(c(/C=C(/C(N2)=O)\SC2=O)ccc2)c2Cl)=O)ncc1 VWJNQFFHSJTVGQ-CJAAZZPWSA-N 0.000 description 1
- WLDPWZQYAVZTTP-UHFFFAOYSA-N C[n]1c(C(O)=O)ncc1 Chemical compound C[n]1c(C(O)=O)ncc1 WLDPWZQYAVZTTP-UHFFFAOYSA-N 0.000 description 1
- NJYIOPRYGAGQCB-ISAHRAOESA-N N[C@@H](CC1)CN1c(c(/C=C(/C(N1)=O)\SC1=O)ccc1)c1Cl Chemical compound N[C@@H](CC1)CN1c(c(/C=C(/C(N1)=O)\SC1=O)ccc1)c1Cl NJYIOPRYGAGQCB-ISAHRAOESA-N 0.000 description 1
- MCUJKPPARUPFJM-UWCCDQBKSA-N N[C@H](CCC1)CN1c1c(/C=C(/C(N2)=O)\SC2=O)cccc1-c1ccccc1 Chemical compound N[C@H](CCC1)CN1c1c(/C=C(/C(N2)=O)\SC2=O)cccc1-c1ccccc1 MCUJKPPARUPFJM-UWCCDQBKSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N O=C(CS1)NC1=O Chemical compound O=C(CS1)NC1=O ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7763908P | 2008-07-02 | 2008-07-02 | |
| US61/077,639 | 2008-07-02 | ||
| US18327809P | 2009-06-02 | 2009-06-02 | |
| US61/183,278 | 2009-06-02 | ||
| PCT/GB2009/050773 WO2010001169A2 (en) | 2008-07-02 | 2009-07-02 | Chemical compounds 251 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013031176A Division JP2013139459A (ja) | 2008-07-02 | 2013-02-20 | 化学化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011526616A JP2011526616A (ja) | 2011-10-13 |
| JP2011526616A5 JP2011526616A5 (https=) | 2013-04-11 |
| JP5261575B2 true JP5261575B2 (ja) | 2013-08-14 |
Family
ID=41050276
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515631A Expired - Fee Related JP5261575B2 (ja) | 2008-07-02 | 2009-07-02 | 化学化合物 |
| JP2013031176A Ceased JP2013139459A (ja) | 2008-07-02 | 2013-02-20 | 化学化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013031176A Ceased JP2013139459A (ja) | 2008-07-02 | 2013-02-20 | 化学化合物 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8901307B2 (https=) |
| EP (1) | EP2310010A2 (https=) |
| JP (2) | JP5261575B2 (https=) |
| KR (1) | KR20110031367A (https=) |
| CN (2) | CN103804371A (https=) |
| AR (1) | AR072791A1 (https=) |
| AU (1) | AU2009265362B2 (https=) |
| BR (1) | BRPI0914599A2 (https=) |
| CA (1) | CA2729557A1 (https=) |
| CL (1) | CL2010001636A1 (https=) |
| CO (1) | CO6341555A2 (https=) |
| CR (1) | CR20110016A (https=) |
| DO (1) | DOP2010000408A (https=) |
| EA (1) | EA018989B1 (https=) |
| EC (1) | ECSP10010735A (https=) |
| HN (1) | HN2010002786A (https=) |
| IL (1) | IL210127A0 (https=) |
| MX (1) | MX2010014233A (https=) |
| MY (1) | MY155961A (https=) |
| NI (1) | NI201100007A (https=) |
| NZ (1) | NZ590859A (https=) |
| PE (1) | PE20120304A1 (https=) |
| SV (1) | SV2011003786A (https=) |
| TW (1) | TWI461423B (https=) |
| UY (1) | UY31952A (https=) |
| WO (1) | WO2010001169A2 (https=) |
| ZA (1) | ZA201100844B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013139459A (ja) * | 2008-07-02 | 2013-07-18 | Astrazeneca Ab | 化学化合物 |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 |
| SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| PT3354652T (pt) | 2010-03-10 | 2020-07-20 | Incyte Holdings Corp | Derivados de piperidin-4-ilazetidina como inibidores de jak1 |
| RS54824B1 (sr) | 2010-05-21 | 2016-10-31 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| JP6057907B2 (ja) * | 2011-10-04 | 2017-01-11 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とする医薬品 |
| WO2013146932A1 (ja) * | 2012-03-30 | 2013-10-03 | ロート製薬株式会社 | 新規ベンジリデンアゾリジン誘導体またはその塩 |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| CN113384546A (zh) | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| RS60244B1 (sr) | 2013-01-15 | 2020-06-30 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| WO2014138168A1 (en) | 2013-03-06 | 2014-09-12 | Incyte Corporation | Processes and intermediates for making a jak inhibitor |
| JP6378918B2 (ja) * | 2013-04-03 | 2018-08-22 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とするＰｉｍ阻害剤 |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| SG10201801069QA (en) | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| CN105658653A (zh) | 2013-08-23 | 2016-06-08 | 因赛特公司 | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 |
| WO2015046390A1 (ja) * | 2013-09-27 | 2015-04-02 | ロート製薬株式会社 | 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
| TW201601769A (zh) * | 2013-09-27 | 2016-01-16 | 樂敦製藥股份有限公司 | 皮膚外用組成物 |
| WO2015122504A1 (ja) * | 2014-02-13 | 2015-08-20 | 国立大学法人 東京大学 | キナーゼ阻害剤 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| JP5857104B2 (ja) * | 2014-06-17 | 2016-02-10 | ロート製薬株式会社 | ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| WO2016100391A1 (en) | 2014-12-15 | 2016-06-23 | Prosetta Antiviral, Inc. | 2-phenethenyltetrahydro isoquinolines useful as anti-hiv compounds |
| CN105985298B (zh) * | 2015-02-10 | 2018-02-23 | 湖南大学 | 2‑[(5‑卤噻唑‑2‑基)亚氨基]‑5‑亚苄基噻唑啉酮及其制备方法与应用 |
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| CN106032365B (zh) * | 2015-03-11 | 2018-03-23 | 湖南大学 | 2‑(噻唑‑2‑基)亚氨基‑5‑亚苄基噻唑啉酮及其制备方法与应用 |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| DK3439667T3 (da) | 2016-04-05 | 2024-04-02 | Immune Sensor Llc | Cgas antagonist forbindelser |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| CA3026211A1 (en) | 2016-06-13 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as inhibitors of dnmt1 |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| KR102642823B1 (ko) * | 2017-06-30 | 2024-03-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 모발 성장을 조절하기 위한 조성물 및 방법 |
| US11319320B2 (en) | 2017-11-06 | 2022-05-03 | Snap Bio, Inc. | PIM kinase inhibitor compositions, methods, and uses thereof |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| EA202091830A1 (ru) | 2018-01-30 | 2020-12-29 | Инсайт Корпорейшн | Способы и промежуточные соединения для получения ингибитора jak |
| MD3773593T2 (ro) | 2018-03-30 | 2024-10-31 | Incyte Corp | Tratament hidradenitei supurative utilizând inhibitori ai JAK |
| WO2019209083A1 (ko) * | 2018-04-26 | 2019-10-31 | 재단법인 의약바이오컨버젼스연구단 | mTOR 저해제로서의 신규 화합물 및 이의 용도 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| EP4172159A4 (en) | 2020-06-30 | 2024-01-10 | The Regents of the University of California | Compositions and methods for modulating hair growth |
| WO2022086920A1 (en) * | 2020-10-20 | 2022-04-28 | Blacksmith Medicines, Inc. | Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| WO2023039170A1 (en) * | 2021-09-09 | 2023-03-16 | Musc Foundation For Research Development | Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy |
| CN116354901B (zh) * | 2023-04-12 | 2024-04-26 | 郑州大学 | 一种噻唑烷二酮类化合物及其制备方法和应用 |
| WO2025017207A1 (en) | 2023-07-20 | 2025-01-23 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Inhibitors of smndc1 and their therapeutic use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE62214B1 (en) * | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
| NO305987B1 (no) | 1994-04-11 | 1999-08-30 | Sankyo Co | Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse |
| JP3668291B2 (ja) * | 1995-06-16 | 2005-07-06 | 久光製薬株式会社 | 新規なピペリジン誘導体 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| UA56185C2 (uk) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
| TW577875B (en) * | 1997-01-31 | 2004-03-01 | Shionogi & Co | Pyrrolidine derivatives with inhibitory activity for phospholipase A2 |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EP1109796A1 (en) * | 1999-07-01 | 2001-06-27 | Geron Corporation | Telomerase inhibitors and methods of their use |
| TW593293B (en) * | 1999-08-23 | 2004-06-21 | Kyorin Seiyaku Kk | Substituted benzylthiazolidine-2,4-dione derivatives |
| HUP0202520A3 (en) * | 1999-08-23 | 2004-11-29 | Kyorin Seiyaku Kk | Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them |
| WO2001034133A2 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| US6452014B1 (en) * | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
| CN1681811B (zh) | 2002-07-10 | 2010-05-26 | 默克雪兰诺有限公司 | 唑烷酮-乙烯基稠合的-苯衍生物 |
| CN1774246A (zh) * | 2003-04-18 | 2006-05-17 | 因齐特圣迭戈公司 | 用于治疗代谢失调、癌症和其它疾病的取代异色满化合物 |
| US7531556B2 (en) * | 2004-04-28 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| US7714005B2 (en) | 2004-12-22 | 2010-05-11 | The Ohio State University Research Foundation | Small molecule Bcl-xL/Bcl-2 binding inhibitors |
| EP2217235A4 (en) * | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| TWI461423B (zh) * | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物 |
-
2009
- 2009-07-01 TW TW098122261A patent/TWI461423B/zh not_active IP Right Cessation
- 2009-07-01 UY UY0001031952A patent/UY31952A/es not_active Application Discontinuation
- 2009-07-02 MX MX2010014233A patent/MX2010014233A/es active IP Right Grant
- 2009-07-02 EP EP09772849A patent/EP2310010A2/en not_active Withdrawn
- 2009-07-02 CN CN201410037508.9A patent/CN103804371A/zh active Pending
- 2009-07-02 US US13/000,138 patent/US8901307B2/en not_active Expired - Fee Related
- 2009-07-02 PE PE2010001221A patent/PE20120304A1/es not_active Application Discontinuation
- 2009-07-02 NZ NZ590859A patent/NZ590859A/xx not_active IP Right Cessation
- 2009-07-02 CA CA2729557A patent/CA2729557A1/en not_active Abandoned
- 2009-07-02 BR BRPI0914599A patent/BRPI0914599A2/pt not_active IP Right Cessation
- 2009-07-02 JP JP2011515631A patent/JP5261575B2/ja not_active Expired - Fee Related
- 2009-07-02 CN CN200980134849.5A patent/CN102137666B/zh not_active Expired - Fee Related
- 2009-07-02 EA EA201100119A patent/EA018989B1/ru not_active IP Right Cessation
- 2009-07-02 AU AU2009265362A patent/AU2009265362B2/en not_active Ceased
- 2009-07-02 WO PCT/GB2009/050773 patent/WO2010001169A2/en not_active Ceased
- 2009-07-02 MY MYPI2010006322A patent/MY155961A/en unknown
- 2009-07-02 AR ARP090102486A patent/AR072791A1/es unknown
- 2009-07-02 KR KR1020117002754A patent/KR20110031367A/ko not_active Ceased
-
2010
- 2010-12-20 IL IL210127A patent/IL210127A0/en unknown
- 2010-12-30 EC EC2010010735A patent/ECSP10010735A/es unknown
- 2010-12-30 CL CL2010001636A patent/CL2010001636A1/es unknown
- 2010-12-30 DO DO2010000408A patent/DOP2010000408A/es unknown
- 2010-12-30 HN HN2010002786A patent/HN2010002786A/es unknown
-
2011
- 2011-01-03 SV SV2011003786A patent/SV2011003786A/es unknown
- 2011-01-05 NI NI201100007A patent/NI201100007A/es unknown
- 2011-01-10 CR CR20110016A patent/CR20110016A/es unknown
- 2011-02-01 CO CO11011427A patent/CO6341555A2/es active IP Right Grant
- 2011-02-01 ZA ZA2011/00844A patent/ZA201100844B/en unknown
-
2013
- 2013-02-20 JP JP2013031176A patent/JP2013139459A/ja not_active Ceased
-
2014
- 2014-07-24 US US14/339,981 patent/US20150051185A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013139459A (ja) * | 2008-07-02 | 2013-07-18 | Astrazeneca Ab | 化学化合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5261575B2 (ja) | 化学化合物 | |
| CN114269735B (zh) | 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用 | |
| ES2313991T3 (es) | Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa. | |
| CN101679401B (zh) | 用于治疗肿瘤的作为met激酶抑制剂的2-氧代-3-苄基-苯并*唑-2-酮衍生物及相关化合物 | |
| KR102014478B1 (ko) | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 | |
| WO2015140133A1 (en) | Piperidine-dione derivatives | |
| CN102596923A (zh) | 1，2，4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途 | |
| EP3307715A1 (en) | Aromatic sulfonamide derivatives | |
| JP6559699B2 (ja) | 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用 | |
| JP2012529513A (ja) | トリアジン誘導体類及びそれらの治療応用 | |
| EP4188929B1 (en) | Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof | |
| EP3587411B1 (en) | 1-(alpha-methylbenzyl)-5-(piperidinomethyl)imidazole derivatives and uses thereof for improving the pharmacokinetics of a drug | |
| CA3134635A1 (en) | Pyrrole compounds | |
| WO2005103012A1 (ja) | ヒドラジノ複素環ニトリル化合物およびその用途 | |
| JP7190755B2 (ja) | オキサジノキナゾリンおよびオキサジノキノリン系化合物、ならびに調製方法およびその使用 | |
| EA016300B1 (ru) | НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB | |
| KR101457027B1 (ko) | 트리아진 유도체와 이들의 치료적 용도 | |
| CN115109061B (zh) | 三环化合物 | |
| EA046720B1 (ru) | Соединения пиррола | |
| KR20210048701A (ko) | 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 | |
| HK40042713A (en) | Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof | |
| HK40042713B (en) | Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof | |
| HK1142333A (en) | 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors | |
| BRPI0719333B1 (pt) | Imidazotriazinas e imidazopirimidinas como inibidores de cinase, composição farmacêutica que as compreende e métodos in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130220 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20130220 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20130307 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130329 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130426 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160502 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |